EA028402B1 - Хинолоновые производные - Google Patents

Хинолоновые производные Download PDF

Info

Publication number
EA028402B1
EA028402B1 EA201591195A EA201591195A EA028402B1 EA 028402 B1 EA028402 B1 EA 028402B1 EA 201591195 A EA201591195 A EA 201591195A EA 201591195 A EA201591195 A EA 201591195A EA 028402 B1 EA028402 B1 EA 028402B1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydroxy
oxo
dihydroquinoline
alkyl
carboxamido
Prior art date
Application number
EA201591195A
Other languages
English (en)
Russian (ru)
Other versions
EA201591195A1 (ru
Inventor
Ранджит К. Десаи
Враджеш Пандия
Панкадж Р. Пател
Original Assignee
Кадила Хелзкэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA028402(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кадила Хелзкэр Лимитед filed Critical Кадила Хелзкэр Лимитед
Publication of EA201591195A1 publication Critical patent/EA201591195A1/ru
Publication of EA028402B1 publication Critical patent/EA028402B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
EA201591195A 2012-12-24 2013-12-23 Хинолоновые производные EA028402B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3600MU2012 2012-12-24
PCT/IN2013/000796 WO2014102818A1 (en) 2012-12-24 2013-12-23 Novel quinolone derivatives

Publications (2)

Publication Number Publication Date
EA201591195A1 EA201591195A1 (ru) 2015-10-30
EA028402B1 true EA028402B1 (ru) 2017-11-30

Family

ID=54148255

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591195A EA028402B1 (ru) 2012-12-24 2013-12-23 Хинолоновые производные

Country Status (26)

Country Link
US (1) US9394300B2 (Direct)
EP (1) EP2935221B1 (Direct)
JP (1) JP6026013B2 (Direct)
KR (1) KR101733901B1 (Direct)
CN (1) CN104903295B (Direct)
AP (1) AP2015008502A0 (Direct)
AR (1) AR094300A1 (Direct)
AU (1) AU2013368843B2 (Direct)
BR (1) BR112015014222B1 (Direct)
CA (1) CA2894636C (Direct)
CL (1) CL2015001802A1 (Direct)
EA (1) EA028402B1 (Direct)
ES (1) ES2660288T3 (Direct)
IL (1) IL239109B (Direct)
JO (1) JO3781B1 (Direct)
MA (1) MA38138A1 (Direct)
MX (1) MX373392B (Direct)
MY (1) MY175854A (Direct)
NZ (1) NZ708605A (Direct)
PH (1) PH12015501452B1 (Direct)
SG (1) SG11201504458XA (Direct)
TR (1) TR201802305T4 (Direct)
TW (1) TWI598339B (Direct)
UA (1) UA117122C2 (Direct)
WO (1) WO2014102818A1 (Direct)
ZA (1) ZA201503814B (Direct)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2959688C (en) * 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
WO2018205928A1 (zh) 2017-05-09 2018-11-15 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2021181360A1 (en) * 2020-03-13 2021-09-16 Cadila Healthcare Limited Novel salts of quinolone compounds
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
EP4157233A4 (en) * 2020-05-29 2024-06-26 Zydus Lifesciences Limited TREATMENT OF PSORIASIS AND INFLAMMATORY SKIN DISEASES
WO2021245533A1 (en) * 2020-06-01 2021-12-09 Cadila Healthcare Limited Treatment for the inflammatory bowel disease
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
BR112023018949A2 (pt) * 2021-03-19 2023-10-17 Zydus Lifesciences Ltd Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto
CN116997331A (zh) * 2021-03-19 2023-11-03 兹杜斯生命科学有限公司 固体形式的喹诺酮化合物及其制备方法
WO2022238745A1 (en) * 2021-05-14 2022-11-17 Zydus Lifesciences Limited Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113549011B (zh) * 2021-08-10 2023-05-09 广东东阳光药业有限公司 德度司他的共晶或盐及其制备方法和用途
CA3227178A1 (en) * 2021-09-20 2023-03-23 Zydus Lifesciences Limited Desidustat particles and compositions thereof
US20250387385A1 (en) * 2022-06-24 2025-12-25 Zydus Lifesciences Limited Treatment for glomerular diseases
WO2024028744A1 (en) * 2022-08-01 2024-02-08 Zydus Lifesciences Limited Treatment for aplastic anemia (aa)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2008138060A1 (en) * 2007-05-16 2008-11-20 Cowper Norman T System and method for maximising solids concentration of slurry pumped through a pipeline

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
EP1644336B1 (en) 2003-06-06 2011-01-19 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
ATE513833T1 (de) * 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2008010964A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
AU2007334321B2 (en) * 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CN101663037A (zh) * 2007-04-18 2010-03-03 默克公司 新的1,8-二氮杂萘化合物
AU2008241483B2 (en) * 2007-04-18 2011-03-24 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2008248234B2 (en) * 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CA2685219C (en) * 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
JP2011505367A (ja) * 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
CN101951776A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢-1h-吡咯稠合吡啶酮
CN101951775A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢噻吩并吡啶
WO2009108496A1 (en) * 2008-02-25 2009-09-03 Merck & Co., Inc. Tetrahydrofuropyridones
JP2011525924A (ja) * 2008-06-25 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US8283465B2 (en) 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2013502399A (ja) * 2009-08-20 2013-01-24 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なキノリン系ヘプシジン拮抗薬
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
US9034851B2 (en) 2011-09-23 2015-05-19 Merck Sharp & Dohme Corp. Substituted pyrimidines
JPWO2013115265A1 (ja) * 2012-01-31 2015-05-11 富山化学工業株式会社 抗ｈｉｖ活性を有する複素環化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2008138060A1 (en) * 2007-05-16 2008-11-20 Cowper Norman T System and method for maximising solids concentration of slurry pumped through a pipeline

Also Published As

Publication number Publication date
MX2015008233A (es) 2015-09-29
UA117122C2 (uk) 2018-06-25
CA2894636C (en) 2018-04-03
ES2660288T3 (es) 2018-03-21
US9394300B2 (en) 2016-07-19
EP2935221B1 (en) 2018-02-07
BR112015014222A2 (pt) 2017-07-11
CN104903295A (zh) 2015-09-09
ZA201503814B (en) 2016-05-25
JP2016503052A (ja) 2016-02-01
AR094300A1 (es) 2015-07-22
JP6026013B2 (ja) 2016-11-16
MY175854A (en) 2020-07-14
CA2894636A1 (en) 2014-07-03
WO2014102818A1 (en) 2014-07-03
AU2013368843B2 (en) 2016-02-25
PH12015501452B1 (en) 2018-06-06
BR112015014222B1 (pt) 2022-12-06
CL2015001802A1 (es) 2015-10-02
US20150299193A1 (en) 2015-10-22
EP2935221A1 (en) 2015-10-28
IL239109B (en) 2019-07-31
CN104903295B (zh) 2017-09-01
TR201802305T4 (tr) 2018-03-21
PH12015501452A1 (en) 2015-09-21
JO3781B1 (ar) 2021-01-31
HK1211022A1 (en) 2016-05-13
TW201441196A (zh) 2014-11-01
KR101733901B1 (ko) 2017-05-08
EA201591195A1 (ru) 2015-10-30
AP2015008502A0 (en) 2015-06-30
MX373392B (es) 2020-04-20
SG11201504458XA (en) 2015-07-30
IL239109A0 (en) 2015-07-30
TWI598339B (zh) 2017-09-11
KR20150085535A (ko) 2015-07-23
AU2013368843A1 (en) 2015-06-18
MA38138A1 (fr) 2016-11-30
NZ708605A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
EA028402B1 (ru) Хинолоновые производные
ES2964964T3 (es) Compuestos bicíclicos puenteados como moduladores del receptor X farnesoide
WO2023062575A1 (en) Cyclic vinyl sulfone compounds as wrn inhibitors
KR102885020B1 (ko) 벤조티오펜 화합물, 이의 제조 방법 및 용도
KR20210028144A (ko) Atf6 저해제 및 그의 용도
JP6768083B2 (ja) 抗腫瘍剤およびブロモドメイン阻害剤
KR20160067841A (ko) 헤테로사이클릭 화합물 및 사용 방법
CN114258391A (zh) 吡咯化合物
CN112513011A (zh) 苯衍生物
TW202229232A (zh) 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之吲哚酮衍生物的製備
CN112110944B (zh) 一种化合物及其制备方法和应用
HK1211022B (en) Quinolone derivatives
JP2009519322A (ja) ｐ３８ＭＡＰキナーゼインヒビターとしてのスルホキシイミン誘導体
HK40048484A (en) Benzene derivative
OA17332A (en) Novel quinolone derivatives.
CN113710666A (zh) 半胱天冬酶抑制剂的前药

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM